GD2-CAR-T / Royal Adelaide Hospital - LARVOL DELTA

Low dose intravenous autologous third generation GD2-CAR-T cell therapy in diffuse midline glioma patients: anti-tumour activity with minimal toxicity (ISPNO 2026) - "The GD2-CAR-T product under investigation features a distinct design with third-generation (14g2a.OX40.CD28.zeta) signalling and, in contrast to previous studies, is administered in combination with anti-VEGF therapy (bevacizumab) to counteract potential oedema from on-target, on-tumour CAR-T effects after lymphodepleting chemotherapy (fludarabine/cyclophosphamide). Our results indicate anti-tumour activity of IV low-dose third-generation GD2-CAR-T administered with anti-VEGF therapy after radiotherapy. Dose escalation continues in the ongoing trial and this will further investigate regimen safety, efficacy and help determine the optimal therapeutic dose."

CAR T-Cell Therapy • Clinical • Brain Cancer • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor • GZMB

Initial clinical and laboratory results of an ongoing dose escalation study of autologous GD2-CAR-T cells in patients with recurrent GD2-positive glioblastoma (AACR 2026) - P | "GD2-CAR-T cell therapy was feasible and safe. CAR-T expanded even without LD chemotherapy. Limited clinical activity was observed with evidence of transient tumour stabilisation."

CAR T-Cell Therapy • Clinical • IO biomarker • Brain Cancer • Diffuse Midline Glioma • Glioblastoma • Neuroblastoma • Oncology • Solid Tumor • CCL2 • CXCL10

In vivo expansion of autologous GD2-CAR-T cells in patients with aggressive primary tumors may be impaired by previous alkylator therapy (AACR 2025) - P | "GD2 is a validated cancer immunotherapy target and has a highly restricted normal tissue expression. Our data suggest that patient selection may be an important parameter to consider when enrolling glioblastoma patients to clinical trials of CAR-T cell therapy. For example, randomized controlled trial evidence indicates that patients who are considering such trials and whose tumors lack MGMT promoter methylation may reasonably be spared exposure to six months of consolidation temozolomide chemotherapy as part of the conventional treatment protocol."

CAR T-Cell Therapy • IO biomarker • Preclinical • Brain Cancer • CNS Tumor • Diffuse Midline Glioma • Glioblastoma • Glioma • Neuroblastoma • Oncology • Solid Tumor • MGMT

Myeloid cell rebound associated with GD2-CAR-T cell therapy in solid tumor patients (AACR 2024) - P, P1 | "Typically, serum levels of inflammatory cytokines and chemokines such as TNF, IL-6, IL-8, CCL2, GM-CSF, and CXCL10, were detected only after the CAR-T cell infusion with variable patterns of the timing and concentration of analyte observed among the 12 patients.At the time of writing, blood samples from the first KARPOS patient showed CAR-T cell expansion and the subsequent increases in circulating myeloid derived suppressor cells and inflammatory cytokines. We expect that full data sets for these parameters will be presented for current and future enrolled patients to both studies.To improve CAR-T cell persistence in solid tumor patients, these data indicate the need for new therapeutic strategies to mitigate effects of CAR-T cell induced myeloid cells with antitumor activity."

CAR T-Cell Therapy • Clinical • IO biomarker • Brain Cancer • CNS Tumor • Colorectal Cancer • Diffuse Midline Glioma • Gastrointestinal Cancer • Glioblastoma • Glioma • Melanoma • Neuroblastoma • Oncology • Sarcoma • Solid Tumor • CCL2 • CSF2 • CXCL10 • CXCL8 • IL6

IMMUNE CELL THERAPY AFTER TCRΑΒ⁺/CD19⁺-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED HIGH-RISK NEUROBLASTOMA: A PHASE 2 SINGLE-CENTER STUDY (EBMT 2026) - "Two patients are disease-free at 1 and 2.7 years after haplo-HSCT, respectively; two experienced local relapse at 10 and 11 months after haplo-HSCT and started local radiotherapy plus temozolomide, which is ongoing; and one patient developed a local relapse 13 months after haplo-HSCT and achieved a second complete remission following local radiotherapy, topotecan, and consolidation with anti-GD2 CAR-T therapy, remaining stable 14 months after relapse. Preliminary data demonstrate the feasibility and safety of haplo-HSCT followed by immunotherapy with dinutuximab beta and NK cell infusions in relapsed HR neuroblastoma. This approach shows promise for improving immune control of disease. Long-term efficacy will be assessed with a larger cohort and extended follow-up."

Clinical • Immune cell • P2 data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Neuroblastoma • Solid Tumor • Transplant Rejection • Transplantation